Latest Commercialisation News

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Metal Powder Works Limited (MPW) has landed a $1 million contract with the US Navy for its innovative expeditionary DirectPowder™ unit, while expanding its alloy portfolio and customer base amid a $15 million capital raise.

Wide Open Agriculture has developed a novel lupin protein milk formulation that overcomes longstanding technological hurdles, lodging a patent to protect its innovation and gearing up for global commercialisation.

Locksley Resources has produced the first 100% American made antimony ingot in decades, validating a fully domestic mine-to-metal supply chain and advancing U.S. critical minerals independence.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

Aquirian Limited has secured a $2.3 million strategic placement with Topgroup and signed a non-binding Memorandum of Understanding to form Drillforce WA, a 50 – 50 joint venture combining their drilling and blasting expertise.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

PARKD Limited has successfully closed its Share Purchase Plan, raising $220,000; well above the initial $120,000 target; following a recent $780,000 placement. This capital boost underscores strong shareholder confidence in the company’s innovative building solutions.

Archer Materials has entered a strategic collaboration with Emergence Quantum to fast-track the development of graphene-based quantum devices, aiming to bridge cutting-edge science with commercial applications.

Orthocell has raised $30 million through an institutional placement to accelerate the US commercialisation of its flagship nerve repair product Remplir and expand its regenerative medicine portfolio.

INOVIQ Limited has completed a $9.5 million placement to institutional investors and launched a $2 million Share Purchase Plan for existing shareholders, aiming to bolster its cancer diagnostics and therapeutics pipeline.

Adveritas Limited has reported a record annualised recurring revenue of $12.2 million for the September 2025 quarter, driven by strong affiliate momentum and initial commercialisation of its Meta integration. The company is advancing its US expansion with a robust trial pipeline and expects significant contract conversions in the coming quarter.